Filariasis in Africa--treatment challenges and prospects.
Identifieur interne : 004E80 ( Main/Exploration ); précédent : 004E79; suivant : 004E81Filariasis in Africa--treatment challenges and prospects.
Auteurs : A. Hoerauf [Allemagne] ; K. Pfarr ; S. Mand ; A Y Debrah ; S. SpechtSource :
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [ 1469-0691 ] ; 2011.
Descripteurs français
- KwdFr :
- Afrique (épidémiologie), Albendazole (effets indésirables), Albendazole (pharmacologie), Albendazole (usage thérapeutique), Animaux, Filaricides (pharmacologie), Filaricides (usage thérapeutique), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (épidémiologie), Humains, Ivermectine (effets indésirables), Ivermectine (pharmacologie), Ivermectine (usage thérapeutique), Onchocerca volvulus (microbiologie), Onchocerca volvulus (pathogénicité), Onchocerca volvulus (physiologie), Onchocercose (traitement médicamenteux), Onchocercose (épidémiologie), Symbiose, Wolbachia (physiologie), Wuchereria bancrofti (microbiologie), Wuchereria bancrofti (pathogénicité), Wuchereria bancrofti (physiologie).
- MESH :
- effets indésirables : Albendazole, Ivermectine.
- microbiologie : Onchocerca volvulus, Wuchereria bancrofti.
- pathogénicité : Onchocerca volvulus, Wuchereria bancrofti.
- pharmacologie : Albendazole, Filaricides, Ivermectine.
- physiologie : Onchocerca volvulus, Wolbachia, Wuchereria bancrofti.
- traitement médicamenteux : Filariose lymphatique, Onchocercose.
- usage thérapeutique : Albendazole, Filaricides, Ivermectine.
- épidémiologie : Afrique, Filariose lymphatique, Onchocercose.
- Animaux, Humains, Symbiose.
English descriptors
- KwdEn :
- Africa (epidemiology), Albendazole (adverse effects), Albendazole (pharmacology), Albendazole (therapeutic use), Animals, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Filaricides (pharmacology), Filaricides (therapeutic use), Humans, Ivermectin (adverse effects), Ivermectin (pharmacology), Ivermectin (therapeutic use), Onchocerca volvulus (microbiology), Onchocerca volvulus (pathogenicity), Onchocerca volvulus (physiology), Onchocerciasis (drug therapy), Onchocerciasis (epidemiology), Symbiosis, Wolbachia (physiology), Wuchereria bancrofti (microbiology), Wuchereria bancrofti (pathogenicity), Wuchereria bancrofti (physiology).
- MESH :
- chemical , adverse effects : Albendazole, Ivermectin.
- geographic , epidemiology : Africa.
- chemical , pharmacology : Albendazole, Filaricides, Ivermectin.
- chemical , therapeutic use : Albendazole, Filaricides, Ivermectin.
- drug therapy : Elephantiasis, Filarial, Onchocerciasis.
- epidemiology : Elephantiasis, Filarial, Onchocerciasis.
- microbiology : Onchocerca volvulus, Wuchereria bancrofti.
- pathogenicity : Onchocerca volvulus, Wuchereria bancrofti.
- physiology : Onchocerca volvulus, Wolbachia, Wuchereria bancrofti.
- Animals, Humans, Symbiosis.
Abstract
Lymphatic filariasis (LF) and onchocerciasis are parasitic nematode infections that are responsible for a major disease burden in the African continent. Disease symptoms are induced by the immune reactions of the host, with lymphoedema and hydrocoele in LF, and dermatitis and ocular inflammation in onchocerciasis. Wuchereria bancrofti and Onchocerca volvulus, the species causing LF and onchocerciasis in Africa, live in mutual symbiosis with Wolbachia endobacteria, which cause a major part of the inflammation leading to symptoms and are antibiotic targets for treatment. The standard microfilaricidal drugs ivermectin and albendazole are used in mass drug administration programmes, with the aim of interrupting transmission, with a consequent reduction in the burden of infection and, in some situations, leading to regional elimination of LF and onchocerciasis. Co-endemicity of Loa loa with W. bancrofti or O. volvulus is an impediment to mass drug administration with ivermectin and albendazole, owing to the risk of encephalopathy being encountered upon administration of ivermectin. Research into new treatment options is exploring several improved delivery strategies for the classic drugs or new antibiotic treatment regimens for anti-wolbachial chemotherapy.
DOI: 10.1111/j.1469-0691.2011.03586.x
PubMed: 21722251
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002552
- to stream PubMed, to step Curation: 002552
- to stream PubMed, to step Checkpoint: 002552
- to stream Ncbi, to step Merge: 004493
- to stream Ncbi, to step Curation: 004493
- to stream Ncbi, to step Checkpoint: 004493
- to stream Main, to step Merge: 004F16
- to stream Main, to step Curation: 004E80
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Filariasis in Africa--treatment challenges and prospects.</title><author><name sortKey="Hoerauf, A" sort="Hoerauf, A" uniqKey="Hoerauf A" first="A" last="Hoerauf">A. Hoerauf</name><affiliation wicri:level="3"><nlm:affiliation>Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund Freud Strasse, Bonn, Germany. hoerauf@microbiology-bonn.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund Freud Strasse, Bonn</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Bonn</settlement></placeName></affiliation></author><author><name sortKey="Pfarr, K" sort="Pfarr, K" uniqKey="Pfarr K" first="K" last="Pfarr">K. Pfarr</name></author><author><name sortKey="Mand, S" sort="Mand, S" uniqKey="Mand S" first="S" last="Mand">S. Mand</name></author><author><name sortKey="Debrah, A Y" sort="Debrah, A Y" uniqKey="Debrah A" first="A Y" last="Debrah">A Y Debrah</name></author><author><name sortKey="Specht, S" sort="Specht, S" uniqKey="Specht S" first="S" last="Specht">S. Specht</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21722251</idno><idno type="pmid">21722251</idno><idno type="doi">10.1111/j.1469-0691.2011.03586.x</idno><idno type="wicri:Area/PubMed/Corpus">002552</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002552</idno><idno type="wicri:Area/PubMed/Curation">002552</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002552</idno><idno type="wicri:Area/PubMed/Checkpoint">002552</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002552</idno><idno type="wicri:Area/Ncbi/Merge">004493</idno><idno type="wicri:Area/Ncbi/Curation">004493</idno><idno type="wicri:Area/Ncbi/Checkpoint">004493</idno><idno type="wicri:Area/Main/Merge">004F16</idno><idno type="wicri:Area/Main/Curation">004E80</idno><idno type="wicri:Area/Main/Exploration">004E80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Filariasis in Africa--treatment challenges and prospects.</title><author><name sortKey="Hoerauf, A" sort="Hoerauf, A" uniqKey="Hoerauf A" first="A" last="Hoerauf">A. Hoerauf</name><affiliation wicri:level="3"><nlm:affiliation>Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund Freud Strasse, Bonn, Germany. hoerauf@microbiology-bonn.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund Freud Strasse, Bonn</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Bonn</settlement></placeName></affiliation></author><author><name sortKey="Pfarr, K" sort="Pfarr, K" uniqKey="Pfarr K" first="K" last="Pfarr">K. Pfarr</name></author><author><name sortKey="Mand, S" sort="Mand, S" uniqKey="Mand S" first="S" last="Mand">S. Mand</name></author><author><name sortKey="Debrah, A Y" sort="Debrah, A Y" uniqKey="Debrah A" first="A Y" last="Debrah">A Y Debrah</name></author><author><name sortKey="Specht, S" sort="Specht, S" uniqKey="Specht S" first="S" last="Specht">S. Specht</name></author></analytic><series><title level="j">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</title><idno type="eISSN">1469-0691</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa (epidemiology)</term><term>Albendazole (adverse effects)</term><term>Albendazole (pharmacology)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Filaricides (pharmacology)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (pharmacology)</term><term>Ivermectin (therapeutic use)</term><term>Onchocerca volvulus (microbiology)</term><term>Onchocerca volvulus (pathogenicity)</term><term>Onchocerca volvulus (physiology)</term><term>Onchocerciasis (drug therapy)</term><term>Onchocerciasis (epidemiology)</term><term>Symbiosis</term><term>Wolbachia (physiology)</term><term>Wuchereria bancrofti (microbiology)</term><term>Wuchereria bancrofti (pathogenicity)</term><term>Wuchereria bancrofti (physiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afrique (épidémiologie)</term><term>Albendazole (effets indésirables)</term><term>Albendazole (pharmacologie)</term><term>Albendazole (usage thérapeutique)</term><term>Animaux</term><term>Filaricides (pharmacologie)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (pharmacologie)</term><term>Ivermectine (usage thérapeutique)</term><term>Onchocerca volvulus (microbiologie)</term><term>Onchocerca volvulus (pathogénicité)</term><term>Onchocerca volvulus (physiologie)</term><term>Onchocercose (traitement médicamenteux)</term><term>Onchocercose (épidémiologie)</term><term>Symbiose</term><term>Wolbachia (physiologie)</term><term>Wuchereria bancrofti (microbiologie)</term><term>Wuchereria bancrofti (pathogénicité)</term><term>Wuchereria bancrofti (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Africa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Albendazole</term><term>Filaricides</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Filaricides</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albendazole</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Onchocerca volvulus</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Onchocerca volvulus</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Onchocerca volvulus</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Onchocerca volvulus</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Albendazole</term><term>Filaricides</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Onchocerca volvulus</term><term>Wolbachia</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Onchocerca volvulus</term><term>Wolbachia</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Onchocercose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Filaricides</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Afrique</term><term>Filariose lymphatique</term><term>Onchocercose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Symbiosis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Symbiose</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphatic filariasis (LF) and onchocerciasis are parasitic nematode infections that are responsible for a major disease burden in the African continent. Disease symptoms are induced by the immune reactions of the host, with lymphoedema and hydrocoele in LF, and dermatitis and ocular inflammation in onchocerciasis. Wuchereria bancrofti and Onchocerca volvulus, the species causing LF and onchocerciasis in Africa, live in mutual symbiosis with Wolbachia endobacteria, which cause a major part of the inflammation leading to symptoms and are antibiotic targets for treatment. The standard microfilaricidal drugs ivermectin and albendazole are used in mass drug administration programmes, with the aim of interrupting transmission, with a consequent reduction in the burden of infection and, in some situations, leading to regional elimination of LF and onchocerciasis. Co-endemicity of Loa loa with W. bancrofti or O. volvulus is an impediment to mass drug administration with ivermectin and albendazole, owing to the risk of encephalopathy being encountered upon administration of ivermectin. Research into new treatment options is exploring several improved delivery strategies for the classic drugs or new antibiotic treatment regimens for anti-wolbachial chemotherapy.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>District de Cologne</li><li>Rhénanie-du-Nord-Westphalie</li></region><settlement><li>Bonn</li></settlement></list><tree><noCountry><name sortKey="Debrah, A Y" sort="Debrah, A Y" uniqKey="Debrah A" first="A Y" last="Debrah">A Y Debrah</name><name sortKey="Mand, S" sort="Mand, S" uniqKey="Mand S" first="S" last="Mand">S. Mand</name><name sortKey="Pfarr, K" sort="Pfarr, K" uniqKey="Pfarr K" first="K" last="Pfarr">K. Pfarr</name><name sortKey="Specht, S" sort="Specht, S" uniqKey="Specht S" first="S" last="Specht">S. Specht</name></noCountry><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Hoerauf, A" sort="Hoerauf, A" uniqKey="Hoerauf A" first="A" last="Hoerauf">A. Hoerauf</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004E80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21722251
|texte= Filariasis in Africa--treatment challenges and prospects.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21722251" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |